EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: A double-blind, randomized clinical trial

Hossein Behzad iD, Sina Mashayekhi, Hila Asham, Parvin Sarbakhsh, Taher Entezari-Maleki iD

Journal of Cardiovascular and Thoracic Research · 25.06.2024 · 16 (2) · 113-119

DOI: 10.34172/jcvtr.33103 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiovascular and Thoracic Research, online erschienen am 25.06.2024. Verfasst von Hossein Behzad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Percutaneous Coronary Intervention (PCI) is a fundamental procedure for coronary artery disease management, yet the risk of adverse events such periprocedural myocardial injury (PMI) persists. This double-blind, randomized clinical trial aims to assess the efficacy of empagliflozin in preventing myocardial injury during PCI procedure.

Methods

A total of 90 patients were randomly assigned to two groups A and B; Group A as the intervention group received empagliflozin 25 mg 24 hours before and empagliflozin 10 mg 1-2 hours before coronary intervention and group Bas the control group received placebo at similar intervals. The primary outcome involved comparing baseline, 8-hour, and 24-hour cTnI and baseline and 24-hour hs-CRP levels after PCI in both groups to measure the incidence of periprocedural myocardial injury (PMI) and anti-inflammatory effects of empagliflozin.

Results

Baseline cTnI levels with P=0.955, 8 hours after PCI with P=0.469, and 24 hours after the intervention with P=0.980 were not statistically different in the two groups. Baseline levels of hs-CRP in both intervention and control groups were not statistically significantly different (P=0.982). Also, there was no statistically significant difference in hs-CRP levels 24 hours after PCI in two groups (P=0.198). Finally, the results showed that MACEs did not occur in any of the groups.

Conclusion

The results of this trial could not express the advantages of acute pretreatment with empagliflozin in preventing PCI-related myocardial injury.

Schlagwörter

Stichwörter der Autor:innen

EmpagliflozinPercutaneous coronary interventionPeriprocedural myocardial injurycTnIhs-CRP

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Department Research Center, Faculty of Public Health, Tabriz University of Medical Sciences, Tabriz, Iran.

ORCID-Profile: Hossein Behzad, Taher Entezari-Maleki

Zitieren

APA

Behzad, H., Mashayekhi, S., Asham, H., Sarbakhsh, P., & Entezari-Maleki, T. (2024). Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: A double-blind, randomized clinical trial. Journal of Cardiovascular and Thoracic Research, 16(2), 113-119. https://doi.org/10.34172/jcvtr.33103

Vancouver

Behzad H, Mashayekhi S, Asham H, Sarbakhsh P, Entezari-Maleki T. Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: A double-blind, randomized clinical trial. Journal of Cardiovascular and Thoracic Research. 2024;16(2):113-119. doi:10.34172/jcvtr.33103

BibTeX
@article{Behzad2024,
  author = {Behzad, Hossein and Mashayekhi, Sina and Asham, Hila and Sarbakhsh, Parvin and Entezari-Maleki, Taher},
  title = {Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: A double-blind, randomized clinical trial},
  journal = {Journal of Cardiovascular and Thoracic Research},
  year = {2024},
  volume = {16},
  number = {2},
  pages = {113--119},
  doi = {10.34172/jcvtr.33103}
}
Kostenlos starten →